2020 issue 2

Back

Volume 36, issue 2

Case report

New psychopharmacotherapy dilemmas associated with COVID-19 – case report

Jolanta Kucharska-Mazur1, Jędrzej Stańczak1, Jerzy Samochowiec1
1. Department of Psychiatry, Pomeranian Medical University in Szczecin
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 149–153
Date of publication: 02-09-2020
DOI: https://doi.org/10.33450/fpn.2020.06.004
Keywords: antipsychotics, chloroquine, SARS-CoV-2

Abstract

Introduction. Due to the current pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is necessary to take therapeutic decisions concerning the simultaneous use of psychopharmacology and drugs supporting the elimination of the virus, especially chloroquine.

Case study. A 36-year-old female patient, with a diagnosis of paranoid schizophrenia, treated with clozapine, zuclopenthixol and lamotrigine, was diagnosed with SARS-CoV-2 infection. Following the recommendations of a specialist of infectious diseases, azithromycin and chloroquine were introduced to the treatment. Due to potential drug interactions, morphology, AST, ALT and ECG were monitored. No abnormalities of monitored parameters were observed. The virus was effectively eliminated.

Comments. With appropriate patient monitoring and care, antipsychotics were successfully combined with chloroquine and azithromycin in short-term therapy of lung inflammatory changes associated with SARS-CoV-2 infection.

Address for correspondence:
dr hab., prof. PUM Jolanta Kucharska-Mazur
Pomorski Uniwersytet Medyczny w Szczecinie
Katedra i Klinika Psychiatrii
ul. Broniewskiego 26, 71-460 Szczecin
email: jola_kucharska@tlen.pl